A Phase 2A Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Varoglutamstat (PQ912) in Patients With Early Alzheimer's Disease With a Stage-Gate to Phase 2B (VIVA-MIND)

This is a Phase 2A multi-center, randomized, double blind, placebo-controlled, parallel group study of varoglutamstat, with a stage gate to Phase 2B.
In Phase 2A there will be adaptive dosing evaluation of three dose levels with exposure to varoglutamstat or placebo for a minimum of 24 weeks, with preliminary evaluation of both cognitive function and pharmacodynamic changes on EEG spectral analysis in approximately 180 participants.
In the event that the stage gate for Phase 2B is reached, then Phase 2B will assesses efficacy and longer-term safety in a larger study group, i.e., 414.

开始日期2021-11-15

申办/合作机构

Vivoryon Therapeutics NV

[+1]

NCT02389413

/ Completed临床2期

A Phase 2A Multicentre, Randomised, Double Blind, Placebo-Controlled, Parallel-Group Safety and Tolerability Study of PQ912 in Subjects With Early Alzheimer's Disease

The aim of this study is to evaluate the safety, tolerability and preliminary efficacy of PQ912 in subjects with Mild Cognitive Impairment (MCI) due to Alzheimers Disease (AD) or mild dementia due to AD.

开始日期2015-03-01

申办/合作机构

Vivoryon Therapeutics NV

[+1]

NCT02190708

/ Completed临床1期

A Phase I, Open Label Study to Assess the Effects of PQ912 on the Pharmacokinetics of Midazolam and Omeprazole in Healthy Male Subjects

Midazolam is a rapid-acting benzodiazepine, with a short half-life (approximately 1.9 hours) and is primarily metabolised by CYP3A.
Omeprazole is a selective proton pump inhibitor substrate used to reduce gastric acid secretion. Omeprazole is primarily metabolised by CYP2C19.
Midazolam and omeprazole are both used as probe drugs in clinical pharmacology studies to evaluate clinical CYP3A and CYP2C19 drug interactions, respectively. Furthermore the EMA and the FDA guidance on drug interactions recommend the use of these drugs for such evaluations.
The aim of this study is to assess the effect of PQ912 on the PK of midazolam and omeprazole. In vitro studies have demonstrated that PQ912 inhibits several CYP enzymes, including CYP3A4 and CYP2C19 and at the expected exposure levels in patients, has the potential to inhibit these enzymes in-vivo. This study is therefore planned to investigate the potential changes in the PK of midazolam and omeprazole due to the effect of PQ912 at steady-state. In clinical practice it is likely that co-administration of PQ912 with other drugs that are metabolised via the CYP3A and/or CYP2C19 enzymes will occur. This study will provide important information for the requirement of dose adjustments or contraindications in these circumstances.

开始日期2014-06-01

申办/合作机构

Vivoryon Therapeutics NV

[+1]

100 项与 Varoglutamstat 相关的临床结果

登录后查看更多信息

100 项与 Varoglutamstat 相关的转化医学

登录后查看更多信息

100 项与 Varoglutamstat 相关的专利（医药）

登录后查看更多信息

项与 Varoglutamstat 相关的文献（医药）

2025-12-01·Alzheimers & Dementia

Generalizability of digital speech and language assessments in MCI/mild AD across four non‐English languages

Article

作者: Schaeffer, Michael ; Xu, Mengdan ; Cormack, Francesca K ; Wenzkowski, Christine ; Lillo, Martina De ; Fuchs, Katharina ; Spilka, Michael J. ; Robin, Jessica

Abstract:

Background:

Neurodegenerative diseases affect speech production. Previous studies show various acoustic and linguistic changes in Mild Cognitive Impairment (MCI) and Alzheimer's disease (AD) speech patterns, such as more pauses and lower usage of nouns. However, most research has focused on English speakers. This analysis examines speech features in MCI and AD patients across four languages to determine if digital speech assessments yield comparable results across different languages.

Method:

This study included 244 patients with MCI or mild AD enrolled in the Phase 2b VIVIAD trial of varoglutamstat, in four language groups: Danish ( n =84), German ( n =59), Dutch ( n =40), and Spanish ( n =61). A picture description task was administered to all patients at baseline using instructions in their respective languages. Five speech features including number of picture objects described, number of nouns, speech rate, pronoun‐to‐noun ratio and average of word length were chosen based on previous analyses of speech patterns in MCI/AD, and a composite score was calculated combining the five measures. We tested the interrelationships among the features in each language and examined whether the speech features were related to another measure of cognitive function, the Mini‐Mental State Exam (MMSE). Associations were examined using a correlational approach.

Result:

There was variation in the magnitudes of the correlations between speech features in the different languages, but the directions of the associations were generally consistent across the four languages in the study. In all four languages, significant correlations with the MMSE were found with both the composite score (‐0.46 ≤ r ≤ ‐0.26) and the object content score (0.27 ≤ r ≤ 0.42).

Conclusion:

Together, these results indicate that there are consistent interrelationships among different speech features across languages. In addition, in the four languages examined, the speech composite score and the number of objects correctly described related to a standard measure of cognition, the MMSE. These results suggest that digital measures of speech and language in MCI/AD are generalizable across languages and relate to cognitive ability more generally. In addition, a composite score of multiple speech features may be more sensitive to cognitive impairment than individual speech metrics.

2025-12-01·Alzheimers & Dementia

The VIVA‐MIND study: Topline Results from Phase 2 RCT of Varoglutamstat in Early AD

Article

作者: Messer, Karen ; Lama, Nicola ; Revta, Carolyn ; Weber, Frank ; Balasubramanian, Archana ; Pol, Alessandra ; Edland, Steven D ; Wenzkowski, Christine ; Jacobs, Diane M. ; Wassmann, Tanja ; Meyer, Antje ; Duehring, Jasmin ; Schell‐Mader, Sylvia ; Leger, Gabriel C ; Schaeffer, Michael ; Zhang, Jing ; Lupo, Jody‐Lynn ; Feldman, Howard H. ; MacKelfresh, Andrew ; Quach, Natalie E

Abstract:

Background:

Varoglutamstat (PQ912) is an oral small molecule inhibitor of glutaminyl cyclases which reduces the pyroglutamate formation of Aβ and CCL2. Preclinical and Ph1 trials support this Ph2 evaluation in early AD. Our objectives included selecting the highest safe and well‐tolerated dose of varoglutamstat with futility analysis at 24 weeks (Ph2A) followed by seamless evaluation of longer‐term safety and efficacy at 72 weeks at this dose (Ph2B).

Method:

Participants with biomarker confirmed early AD were randomized to varoglutamstat or placebo. A sequential design tested 3 descending doses (600mg, 300mg, 150mg BID) using a continuous Pocock safety boundary. A Stage Gate futility analysis of the first 180 subjects at 24 weeks was designed to guide the decision from Ph2A‐B (Figure 1). The Ph2B primary endpoint was CDR‐sum‐of‐boxes (CDR‐SB), with secondary endpoints CFC2, ABC score, spectral EEG, FAQ, ADAS‐Cog‐13, and NPI.

Result:

Table 1 presents baseline characteristics of the 109 randomized and dosed participants. The first dose cohort of varoglutamstat 600mg or placebo did not cross the safety boundary in Ph2A, supporting this dose selection for all participants thereafter. An abbreviated futility analysis was conducted after the trial was terminated prematurely for administrative reasons, with the provisional result of ‘halt enrollment’(yellow) (Figure 1). There were 74% of participants who completed week 24 and 31% week 72 (Figure 2). There were no significant differences between varoglutamstat and placebo in LS mean squares from baseline to week 72 in CDR‐SB (‐0.05 [95% CI ‐1.03, 0.92]), CFC2 (0.97 [95% CI ‐3.34, 5.28]), ABC score (0.10 [95% CI ‐0.10, 0.30]), FAQ (‐0.60 [95% CI ‐4.22, 3.01]), ADAS‐Cog‐13 (2.03 [95% CI ‐2.29, 6.36]); or NPI (‐3.09 [95% CI ‐7.81, 1.62]). At least one TEAE during treatment was reported in 84.9% varoglutamstat and 76.8% placebo with treatment discontinuations due to AE 11.3% varoglutamstat and 3.4% placebo. Severe TEAEs occurred with similar frequencies across arms. Frequency of SAEs/AESIs was 18.9/1.9% varoglutamstat versus 8.9%/5.4% placebo.

Conclusion:

Varoglutamstat was safe and well‐tolerated in this VIVA‐MIND early AD RCT. Efficacy assessment did not demonstrate any significant treatment benefits however, the available sample was limited. Biomarker results and PK/PD are pending.

2025-09-18·JOURNAL OF PHYSICAL CHEMISTRY B

Varoglutamstat Inhibits the Dimerization of the Aβ_25–35 Fragment in Aqueous Solution

Article

作者: Van V. Vu ; Son Tung Ngo ; Trung Hai Nguyen ; Philippe Derreumaux ; Hoang Anh Nguyen

The self-aggregation of amyloid-beta (Aβ) peptides is strongly associated with Alzheimer's disease. In this study, the influence of the small varoglutamstat compound on the conformations of the FAβ_25-35 dimer was extensively characterized by using MD simulations. The influence of the ligand on the conformation of the FAβ_25-35 dimer was studied during the first 10.0 μs. However, its real influence was clarified when the trajectory was extended to 20.0 μs. This indicates that the investigation of a ligand inhibiting Aβ requires a longer MD simulation than previously thought. The ligand changes ensemble properties by reducing the formation of nonbonded intermolecular contacts and β-content. Although varoglutamstat has weak binding to the FAβ_25-35 dimer, the free energy landscape is impacted in shape, free energy barrier, and number of minima. Notably, it is found that the population of the amyloid-competent dimer structure is substantially reduced upon ligand addition. Furthermore, the change from β-hairpin conformation to antiparallel structure may occur through a transition state forming a random coil conformation.

项与 Varoglutamstat 相关的新闻（医药）

2026-04-09

·BioSpace

Vivoryon Therapeutics N.V. to Attend Upcoming Investor Conference

Vivoryon Therapeutics N.V. to Attend Upcoming Investor Conference Halle (Saale) / Munich, Germany, April 9 , 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) ( Vivoryon ), a clinical stage company developing small molecule medicines for inflammatory and fibrotic disorders, with a primary focus on kidney diseases, today announced that the Company’s management will participate in the following investor conference: Van Lanschot Kempen Life Sciences Conference Date: April 16, 2026 Location: Amsterdam, The Netherlands Attendee: Julia Neugebauer, PhD, COO ### About Vivoryon Therapeutics N.V. Vivoryon is a clinical stage biotechnology company focused on developing innovative small molecule-based medicines for the treatment of inflammatory and fibrotic disorders of the kidney. Driven by its passion for ground-breaking science and innovation, the Company strives to improve patient outcomes by changing the course of severe diseases through modulating the activity and stability of pathologically relevant proteins. Vivoryon’s most advanced program, varoglutamstat, a proprietary, first-in-class orally available QPCT/L inhibitor, is being evaluated to treat diabetic kidney disease. Vivoryon Forward Looking Statements This press release includes forward-looking statements, including, without limitation, those regarding the business strategy, management plans and objectives for future operations of Vivoryon Therapeutics N.V. (the “Company”), estimates and projections with respect to the market for the Company’s products and forecasts and statements as to when the Company’s products may be available. Words such as “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “project,” “predict,” “should” and “will” and similar expressions as they relate to the Company are intended to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance; rather they are based on the Management’s current expectations and assumptions about future events and trends, the economy and other future conditions. The forward-looking statements involve a number of known and unknown risks and uncertainties. These risks and uncertainties and other factors could materially adversely affect the outcome and financial effects of the plans and events described herein. The Company’s results of operations, cash needs, financial condition, liquidity, prospects, future transactions, strategies or events may differ materially from those expressed or implied in such forward-looking statements and from expectations. As a result, no undue reliance should be placed on such forward-looking statements. This press release does not contain risk factors. Certain risk factors that may affect the Company’s future financial results are discussed in the published annual financial statements of the Company. This press release, including any forward-looking statements, speaks only as of the date of this press release. The Company does not assume any obligation to update any information or forward-looking statements contained herein, save for any information required to be disclosed by law. For more information, please contact: Investor Contact Vivoryon Therapeutics N.V. Dr. Manuela Bader, Director IR & Communication Email: IR@vivoryon.com LifeSci Advisors Sandya von der Weid Tel: +41 78 680 05 38 Email: svonderweid@lifesciadvisors.com Attachment 2026-04-09_VVY_kempen

2026-03-28

·GlobeNewswire-Health Care

Vivoryon Therapeutics N.V. Provides Update on Growing Body of Evidence Validating Glutaminyl Cyclases as Promising Targets in DKD at World Congress of Nephrology

Vivoryon Therapeutics N.V. Provides Update on Growing Body of Evidence Validating Glutaminyl Cyclases as Promising Targets in DKD at World Congress of Nephrology Halle (Saale) / Munich, Germany, March 28, 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company developing small molecule medicines for inflammatory and fibrotic disorders, with a primary focus on kidney diseases, today announced that new data analyses from the Company’s varoglutamstat Phase 2 program were presented at the World Congress of Nephrology (WCN) held in Yokohama, Japan, March 28-31, 2026. “We are very pleased with the opportunity to share our consistently compelling results with world leading experts in the kidney space at WCN, the International Society of Nephrology’s flagship event,” said Frank Weber, MD, CEO of Vivoryon. “With these new analyses we are able to deliver additional mechanistic proof points showing that inhibition of glutaminyl cyclases can effectively address the underlying molecular changes in diabetic kidney disease. The data continue to strengthen our ongoing development program dedicated to making a meaningful contribution to shaping the future of global kidney care.” Presentation HighlightsVivoryon has thoroughly analyzed kidney function data from the two independent Phase 2 studies VIVIAD and VIVA-MIND, with highly consistent results between the two studies, highlighting the unique potential of varoglutamstat to meaningfully improve kidney function in patients with diabetes. The new analyses presented at WCN underscore previous reports showing that the effect of varoglutamstat on eGFR observed in both studies was greater in elderly participants with diabetes compared to elderly participants without diabetes. In participants with diabetes and lower baseline eGFR (mean 60 mL/min/1.73m2), the effect size was comparable or higher than in the total population of participants with diabetes. Additionally, analysis of data from a DKD mouse model showed significant improvements of inflammation, glomerulosclerosis and kidney function. Taken together, these results add to the growing body of evidence showing that inhibition of glutaminyl cyclases is valid approach to address the underlying inflammatory and fibrotic changes in DKD and support further development of varoglutamstat in patients with diabetes and more advanced CKD stages. Presentation DetailsPresentation Date/Time: March 28, 2026, 5:00 pm JST/9:00 am CET Poster Title: Translational Validation of Glutaminyl-Cyclases as Promising New Target for Treatment of DKD (P334)Venue: Pacifico Yokohama, Yokohama, JapanPresenter: Christine Wenzkowski, PhD, VP Business Development of Vivoryon ### About Vivoryon Therapeutics N.V. Vivoryon is a clinical stage biotechnology company focused on developing innovative small molecule-based medicines for the treatment of inflammatory and fibrotic disorders of the kidney. Driven by its passion for ground-breaking science and innovation, the Company strives to improve patient outcomes by changing the course of severe diseases through modulating the activity and stability of pathologically relevant proteins. Vivoryon’s most advanced program, varoglutamstat, a proprietary, first-in-class orally available QPCT/L inhibitor, is being evaluated to treat diabetic kidney disease. www.vivoryon.com Vivoryon Forward Looking Statements This press release includes forward-looking statements, including, without limitation, those regarding the business strategy, management plans and objectives for future operations of Vivoryon Therapeutics N.V. (the “Company”), estimates and projections with respect to the market for the Company’s products and forecasts and statements as to when the Company’s products may be available. Words such as “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “project,” “predict,” “should” and “will” and similar expressions as they relate to the Company are intended to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance; rather they are based on the Management’s current expectations and assumptions about future events and trends, the economy and other future conditions. The forward-looking statements involve a number of known and unknown risks and uncertainties. These risks and uncertainties and other factors could materially adversely affect the outcome and financial effects of the plans and events described herein. The Company’s results of operations, cash needs, financial condition, liquidity, prospects, future transactions, strategies or events may differ materially from those expressed or implied in such forward-looking statements and from expectations. As a result, no undue reliance should be placed on such forward-looking statements. This press release does not contain risk factors. Certain risk factors that may affect the Company’s future financial results are discussed in the published annual financial statements of the Company. This press release, including any forward-looking statements, speaks only as of the date of this press release. The Company does not assume any obligation to update any information or forward-looking statements contained herein, save for any information required to be disclosed by law. For more information, please contact:Investor ContactVivoryon Therapeutics N.V.Dr. Manuela Bader, Director IR & CommunicationEmail: IR@vivoryon.com LifeSci AdvisorsSandya von der Weid Tel: +41 78 680 05 38Email: svonderweid@lifesciadvisors.com Attachment 2026-03-28_VVY_WCN

临床2期临床结果

2026-03-11

·制药网

又一个阿尔茨海默病药物折戟！攻坚之路任重道远

【制药网行业动态】阿尔茨海默病(AD)是一种中枢神经系统的退行性病变，症状包括记忆障碍，失语，失用，失认以及视空间能力损害等。近年来，一大批药企积极加强对该药物的研发，但是业内也指出，阿尔茨海默病被认为是药物研发的“难关”。　　有数据显示，1998至2017年间阿尔茨海默病新药临床成功率仅为2.7%——146个进入临床试验的药物中，只有4种终获批上市。据悉，近日又有一家药企阿尔茨海默病新药临床试验失败。　　Alector 公司开发的人源化 TREM2 激动型单克隆抗体 AL002 治疗早期阿尔茨海默病的 2 期随机对照临床试验失败，未达主要终点。　　研究结果显示，AL002 在中枢神经系统(CNS)中表现出持续靶点结合和药效学反应，具体表现为脑脊液中可溶性 TREM2 水平降低和骨桥蛋白水平升高。但该临床试验未达到主要终点(临床痴呆评定量表总分较基线的变化)：在第 96 周时，15mg/kg 剂量组、40mg/kg 剂量组、60mg/kg 剂量组与安慰剂组的最小二乘均值差分别为 -0.31、0.13 和 -0.17。最常见的治疗突发不良事件为磁共振成像中出现类似于淀粉样蛋白相关影像学异常(ARIA)变化。　　然而回顾2025年，也有多家药企传出阿尔茨海默病研究失败的消息，如诺和诺德曾于2025年11月宣布，其备受关注的阿尔茨海默病药物试验以失败告终。该试验针对的是司美格鲁肽(semaglutide)的一款旧版口服制剂，结果显示该药物无法延缓这种致脑损伤疾病的进展。此次挫折也让诺和诺德的期望化为泡影 —— 该公司原本希望阿尔茨海默病领域能为司美格鲁肽等 GLP-1(胰高血糖素样肽 - 1)类药物打开一个重要的新市场。目前，诺和诺德在肥胖症和糖尿病这两大核心治疗领域的重磅药物正面临日益激烈的竞争。　　2025年6月，先声药业也被曝停止阿尔茨海默病(AD)药物Varoglutamstat的研发。据观察，在先声药业的网站和新年报中，曾经高调引进的AD管线已不见踪影。据悉，先声药业引进的Varoglutamstat曾一度带来希望，该药物采用了一种 “冷门”作用机制：通过抑制谷氨酰胺酰环化酶活性，阻止具有神经毒性的pE-Aβ形成。在早期的IIa期临床试验中，它显示出对认知改善的积极作用，甚至获得了FDA的“快速通道”资格认定。然而，2024年3月的IIb期临床试验(VIVIAD研究)结果给了所有人沉重一击。研究未能达到主要终点，也未能在认知能力变化方面显示出统计学显著差异，关键次要终点同样全部落空。　　阿尔茨海默病药物研发的失败，背后是其复杂的发病机制。该病病因尚未完全明确，单一靶点的药物往往难以实现突破，即便药物能作用于预设靶点，也未必能转化为临床疗效。同时，临床试验周期长、成本高，且患者个体差异大，也进一步增加了研发难度。　　尽管挫折不断，但药企的攻坚之路从未停止。作为常见的神经退行性疾病，阿尔茨海默病影响着全球约5700万人口，且患病人数仍在持续增长，巨大的医疗需求驱动着行业不断探索。阿尔茨海默病药物研发的道路注定漫长且艰难，每一次失败都是向真相靠近的一步。虽然目前多药企折戟沉沙，但这些探索积累的经验，终将为后续研发指明方向。如上述 Alector研究团队表示，这项 TREM2 激动型抗体治疗早期阿尔茨海默病的临床试验结果为阴性，虽未达到主要终点，但为 TREM2 靶向治疗和 ARIA 研究提供了重要参考。　　免责声明：在任何情况下，本文中的信息或表述的意见，均不构成对任何人的投资建议。

100 项与 Varoglutamstat 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
轻度痴呆	临床2期	中国	江苏先声药业有限公司	2022-04-26
轻度痴呆	临床2期	中国	Vivoryon Therapeutics NV	2022-04-26
轻度痴呆	临床2期	中国	Haupt Pharma Wülfing GmbH	2022-04-26
轻度认知障碍	临床2期	丹麦	Vivoryon Therapeutics NV	2020-07-06
轻度认知障碍	临床2期	丹麦	Nordic Bioscience A/S	2020-07-06
轻度认知障碍	临床2期	德国	Vivoryon Therapeutics NV	2020-07-06
轻度认知障碍	临床2期	德国	Nordic Bioscience A/S	2020-07-06
轻度认知障碍	临床2期	荷兰	Nordic Bioscience A/S	2020-07-06
轻度认知障碍	临床2期	荷兰	Vivoryon Therapeutics NV	2020-07-06
轻度认知障碍	临床2期	波兰	Vivoryon Therapeutics NV	2020-07-06

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03919162 (VIVA-MIND, CTgov)	临床2期	阿尔茨海默症	112	PQ912 (PQ912)	蓋範糧壓蓋遞醖衊網衊 = 鏇廠夢積構壓壓範鹹鏇艱醖網襯艱選範憲鑰製 (獵選簾鑰鹹淵觸觸網築, 遞壓遞選構鬱構鏇壓選 ~ 壓艱積繭蓋願願鏇範選) 更多	-	2025-12-12
				Placebo (Placebo)	蓋範糧壓蓋遞醖衊網衊 = 憲觸齋襯憲糧範繭顧築艱醖網襯艱選範憲鑰製 (獵選簾鑰鹹淵觸觸網築, 積簾觸鬱製蓋壓願範積 ~ 遞膚製蓋艱簾壓繭糧鹹) 更多
NCT03919162 (VIVA-MIND, GlobeNewswire) 人工标引	临床2期	阿尔茨海默症	-	Varoglutamstat	鑰淵齋願糧齋範鹽鏇蓋(廠選範鬱願廠鬱築壓膚) = no clinically meaningful and no statistically significant differences between varoglutamstat 600mg BID and placebo 範廠憲構選淵艱選鑰繭 (艱衊簾艱繭範衊鬱構淵 ) 更多	积极	2024-12-09
				placebo
NCT04498650 (VIVIAD, ASN2024)	临床2期	阿尔茨海默症 \| 轻度认知障碍	259	Varoglutamstat 300 mg	廠廠製構憲繭範蓋襯範(簾衊鏇廠廠齋製鏇簾選) = 膚鹹夢夢鹹鬱觸簾鬱觸蓋糧簾餘廠簾簾襯艱膚 (憲夢艱觸衊鹹願積遞獵 )	积极	2024-10-25
				Varoglutamstat 600 mg	鬱醖淵糧範艱簾窪夢願(窪膚製餘範醖積齋餘齋) = 遞遞衊膚夢鬱膚蓋糧獵鹹壓糧衊簾簾繭夢淵鏇 (簾繭廠齋廠構憲齋築遞 ) 更多
NCT04498650 (VIVIAD, GlobeNewswire \| ASN2024)	临床2期	阿尔茨海默症 \| 糖尿病肾病	32	Varoglutamstat	憲鏇築範構淵範襯齋鏇(簾積網憲憲鹽構簾鏇繭) = 製醖膚糧淵醖築鏇網選衊淵鹽憲窪簾網獵蓋構 (觸網襯積網夢觸願鬱遞 )	积极	2024-10-25
				placebo	憲鏇築範構淵範襯齋鏇(簾積網憲憲鹽構簾鏇繭) = 觸鑰憲鏇齋糧齋願遞襯衊淵鹽憲窪簾網獵蓋構 (觸網襯積網夢觸願鬱遞 )
NCT04498650 (VIVIAD, GlobeNewswire) 人工标引	临床2期	肾脏疾病 CCL2 Expression	-	Varoglutamstat 600mg BID	獵製壓憲齋憲簾願憲壓(鹽鹹鹽窪繭鹹壓壓夢鑰) = 窪鑰糧鑰鏇網積窪顧齋願壓鏇鏇衊選遞遞襯觸 (鏇壓積鹽醖憲鹽壓構憲 ) 更多	积极	2024-09-12
NCT04498650 (VIVIAD, Corporate Publications) 人工标引	临床2期	阿尔茨海默症	250	Varoglutamstat	憲鹹醖網窪簾壓餘選艱(選衊醖製築窪鑰夢糧鹽) = 鑰選簾範夢築壓艱廠鏇鬱憲廠繭簾願糧構廠蓋 (襯襯艱獵壓選鏇網簾壓 ) 更多	积极	2022-07-31
NCT02389413 (Pubmed \| Alzheimers Res Ther) 人工标引	临床2期	阿尔茨海默症	120	PQ912	糧蓋淵夢壓膚衊鏇築選(築壓鏇網餘範願簾鬱網) = There was no significant difference between treatments in the number of subjects with (serious) adverse events, although there were slightly more patients with a serious adverse event in the PQ912 group compared to placebo. 憲餘願衊構糧積醖鏇顧 (選鹹簾窪齋夢鏇簾窪範 ) 更多	积极	2018-10-12
				Placebo